Oragenics, Inc. (NYSEAMERICAN:OGEN) Sees Significant Decrease in Short Interest

Oragenics, Inc. (NYSEAMERICAN:OGEN) saw a significant decrease in short interest in December. As of December 31st, there was short interest totaling 108,196 shares, a decrease of 22.3% from the December 15th total of 139,273 shares. Based on an average daily volume of 70,912 shares, the short-interest ratio is presently 1.5 days. Approximately 2.9% of the company’s shares are sold short. Approximately 2.9% of the company’s shares are sold short. Based on an average daily volume of 70,912 shares, the short-interest ratio is presently 1.5 days.

Oragenics Stock Performance

Shares of NYSEAMERICAN OGEN traded up $0.01 during trading on Tuesday, reaching $0.96. The stock had a trading volume of 17,285 shares, compared to its average volume of 32,595. The company has a market cap of $3.99 million, a P/E ratio of -0.08 and a beta of 0.90. Oragenics has a fifty-two week low of $0.74 and a fifty-two week high of $18.90. The business’s 50-day moving average price is $0.91 and its 200-day moving average price is $1.14.

Oragenics (NYSEAMERICAN:OGEN) last announced its earnings results on Friday, November 7th. The company reported ($1.96) EPS for the quarter.

Hedge Funds Weigh In On Oragenics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clear Street LLC acquired a new position in Oragenics during the 2nd quarter worth $270,000. Sabby Management LLC purchased a new position in shares of Oragenics in the 3rd quarter valued at about $77,000. Finally, Bank of America Corp DE grew its position in shares of Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares in the last quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.